Effects of the sGC stimulator BAY 41-2272 are not mediated by phosphodiesterase 5 inhibition.
Bischoff
Erwin
E
Stasch
Johannes-Peter
JP
D015106:3',5'-Cyclic-GMP Phosphodiesterases; D000225:Adenine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D001011:Aorta / Q000187:drug effects / Q000201:enzymology; D001792:Blood Platelets / Q000187:drug effects / Q000201:enzymology; D016466:CHO Cells / Q000187:drug effects / Q000201:enzymology; D006224:Cricetinae; D003412:Cricetulus; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D005260:Female; D005835:Genitalia / Q000187:drug effects / Q000201:enzymology; D006162:Guanylate Cyclase; D006801:Humans; D008297:Male; D018482:Muscle, Skeletal / Q000187:drug effects / Q000201:enzymology; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D010727:Phosphoric Diester Hydrolases / Q000378:metabolism*; D010879:Piperazines / Q000494:pharmacology; D011687:Purines; D011720:Pyrazoles / Q000008:administration & dosage / Q000494:pharmacology*; D011725:Pyridines / Q000008:administration & dosage / Q000494:pharmacology*; D011817:Rabbits; D051381:Rats; D018160:Receptors, Cytoplasmic and Nuclear / Q000819:agonists*; D000068677:Sildenafil Citrate; D000071756:Soluble Guanylyl Cyclase; D013450:Sulfones
C423582:3-(4-Amino-5-cyclopropylpyrimidine-2-yl)-1-(2-fluorobenzyl)-1H-pyrazolo(3,4-b)pyridine; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D011720:Pyrazoles; D011725:Pyridines; D018160:Receptors, Cytoplasmic and Nuclear; D013450:Sulfones; C010192:9-(2-hydroxy-3-nonyl)adenine; D000068677:Sildenafil Citrate; D010727:Phosphoric Diester Hydrolases; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; C517381:PDE5A protein, human; C517384:Pde5a protein, rat; D006162:Guanylate Cyclase; D000071756:Soluble Guanylyl Cyclase; D000225:Adenine